Literature DB >> 22267854

To biopsy or not to biopsy: is that the only question?

Shaheenah Dawood1, Ana M Gonzalez-Angulo.   

Abstract

Mesh：

Year:  2012        PMID： 22267854      PMCID： PMC3286159          DOI： 10.1634/theoncologist.2011-0432

Source DB:  PubMed          Journal:  Oncologist        ISSN： 1083-7159


× No keyword cloud information.
  10 in total

1.  Estrogen and HER-2 receptor discordance between primary breast cancer and metastasis.

Authors:  Lajos Pusztai; Giuseppe Viale; Catherine M Kelly; Clifford A Hudis
Journal:  Oncologist       Date:  2010-11-01

2.  Molecular alterations between the primary breast cancer and the subsequent locoregional/metastatic tumor.

Authors:  Robyn Macfarlane; Melanie Seal; Caroline Speers; Ryan Woods; Hamad Masoudi; Samuel Aparicio; Stephen K Chia
Journal:  Oncologist       Date:  2012-01-20

3.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications.

Authors:  T Sørlie; C M Perou; R Tibshirani; T Aas; S Geisler; H Johnsen; T Hastie; M B Eisen; M van de Rijn; S S Jeffrey; T Thorsen; H Quist; J C Matese; P O Brown; D Botstein; P E Lønning; A L Børresen-Dale
Journal:  Proc Natl Acad Sci U S A       Date:  2001-09-11       Impact factor: 11.205

Review 4.  The role of chemotherapy for metastatic breast cancer.

Authors:  K D Miller; G W Sledge
Journal:  Hematol Oncol Clin North Am       Date:  1999-04       Impact factor: 3.722

5.  Loss of human epidermal growth factor receptor 2 (HER2) expression in metastatic sites of HER2-overexpressing primary breast tumors.

Authors:  Naoki Niikura; Jun Liu; Naoki Hayashi; Elizabeth A Mittendorf; Yun Gong; Shana L Palla; Yutaka Tokuda; Ana M Gonzalez-Angulo; Gabriel N Hortobagyi; Naoto T Ueno
Journal:  J Clin Oncol       Date:  2011-11-28       Impact factor: 44.544

6.  Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer.

Authors:  Eitan Amir; Naomi Miller; William Geddie; Orit Freedman; Farrah Kassam; Christine Simmons; Maria Oldfield; George Dranitsaris; George Tomlinson; Andreas Laupacis; Ian F Tannock; Mark Clemons
Journal:  J Clin Oncol       Date:  2011-11-28       Impact factor: 44.544

7.  Heterogeneity of breast cancer metastases: comparison of therapeutic target expression and promoter methylation between primary tumors and their multifocal metastases.

Authors:  Julie M Wu; Mary Jo Fackler; Marc K Halushka; Diana W Molavi; M Evangeline Taylor; Wei Wen Teo; Constance Griffin; John Fetting; Nancy E Davidson; Angelo M De Marzo; Jessica L Hicks; Dhananjay Chitale; Marc Ladanyi; Saraswati Sukumar; Pedram Argani
Journal:  Clin Cancer Res       Date:  2008-04-01       Impact factor: 12.531

8.  Gene expression profiles of primary breast tumors maintained in distant metastases.

Authors:  Britta Weigelt; Annuska M Glas; Lodewyk F A Wessels; Anke T Witteveen; Johannes L Peterse; Laura J van't Veer
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-09       Impact factor: 11.205

9.  Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review.

Authors:  Shaheenah Dawood; Kristine Broglio; Aman U Buzdar; Gabriel N Hortobagyi; Sharon H Giordano
Journal:  J Clin Oncol       Date:  2009-11-23       Impact factor: 44.544

10.  Loss of HER2 amplification following trastuzumab-based neoadjuvant systemic therapy and survival outcomes.

Authors:  Elizabeth A Mittendorf; Yun Wu; Maurizio Scaltriti; Funda Meric-Bernstam; Kelly K Hunt; Shaheenah Dawood; Francisco J Esteva; Aman U Buzdar; Huiqin Chen; Sameena Eksambi; Gabriel N Hortobagyi; Jose Baselga; Ana M Gonzalez-Angulo
Journal:  Clin Cancer Res       Date:  2009-11-17       Impact factor: 12.531
  10 in total
  4 in total

1.  Molecular image-directed biopsies: improving clinical biopsy selection in patients with multiple tumors.

Authors:  Stephanie A Harmon; Michael J Tuite; Robert Jeraj
Journal:  Phys Med Biol       Date:  2016-10-03       Impact factor: 3.609

2.  Discordances in estrogen receptor status, progesterone receptor status, and HER2 status between primary breast cancer and metastasis.

Authors:  Elsa Curtit; Virginie Nerich; Laura Mansi; Loic Chaigneau; Laurent Cals; Cristian Villanueva; Fernando Bazan; Philippe Montcuquet; Nathalie Meneveau; Sophie Perrin; Marie-Paule Algros; Xavier Pivot
Journal:  Oncologist       Date:  2013-05-30

3.  Expression of epithelial to mesenchymal transition-related markers in lymph node metastases as a surrogate for primary tumor metastatic potential in breast cancer.

Authors:  Aleksandra Markiewicz; Tomasz Ahrends; Marzena Wełnicka-Jaśkiewicz; Barbara Seroczyńska; Jarosław Skokowski; Janusz Jaśkiewicz; Jolanta Szade; Wojciech Biernat; Anna J Zaczek
Journal:  J Transl Med       Date:  2012-11-19       Impact factor: 5.531

4.  EZH2 and CD79B mutational status over time in B-cell non-Hodgkin lymphomas detected by high-throughput sequencing using minimal samples.

Authors:  Mauro Ajaj Saieg; William R Geddie; Scott L Boerner; Denis Bailey; Michael Crump; Gilda da Cunha Santos
Journal:  Cancer Cytopathol       Date:  2013-01-29       Impact factor: 5.284
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.